InMed Pharmaceuticals Inc.
For the period ended Jun 30, 2026. Filed Sep 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Sep 9, 2026
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Equity
For the years ended June 30, 2026 and 2025
| Common Shares · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total | ||||||
|---|---|---|---|---|---|---|
| # | $ | $ | $ | $ | $ | |
| Balance July 1, 2025 | 2,002,186 | 91,221,174 | 39,322,644 | (117,237,892) | 128,569 | 13,434,495 |
| Proceeds from SEPA (Note 6) | 259,877 | 231,675 | - | - | - | 231,675 |
| Share issuance costs (Note 6) | - | (137,179) | - | - | - | (137,179) |
| Exercise of pre-funded warrants (Note 6) | 3,077,373 | 2,967,028 | (2,967,028) | - | - | - |
| Loss for the period | - | - | - | (12,560,850) | - | (12,560,850) |
| Deemed dividends (Note 6) | - | - | 431,664 | (431,664) | - | - |
| Share-based compensation (Note 7) | - | - | 106,866 | - | - | 106,866 |
| Balance June 30, 2026 | 5,339,436 | 94,282,698 | 36,894,146 | (130,230,406) | 128,569 | 1,075,007 |
| Common Shares · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total | ||||||
|---|---|---|---|---|---|---|
| # | $ | $ | $ | $ | $ | |
| Balance July 1, 2024 | 445,908 | 82,784,400 | 35,368,899 | (109,075,759) | 128,569 | 9,206,109 |
| Proceeds from ATM (Note 6) | 313,242 | 1,905,583 | - | - | - | 1,905,583 |
| Proceeds from SEPA (Note 6) | 1,208,336 | 6,224,716 | - | - | - | 6,224,716 |
| Proceeds from Private Placement (Note 6) | - | - | 5,024,891 | - | - | 5,024,891 |
| Share issuance costs (Note 6) | - | (269,559) | (614,419) | - | - | (883,978) |
| Exercise of pre-funded warrants (Note 6) | 34,700 | 576,034 | (576,034) | - | - | - |
| Loss for the period | - | - | - | (8,162,133) | - | (8,162,133) |
| Share-based compensation (Note 7) | - | - | 119,307 | - | - | 119,307 |
| Balance June 30, 2025 | 2,002,186 | 91,221,174 | 39,322,644 | (117,237,892) | 128,569 | 13,434,495 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.